Medtronic to Buy Twelve for $408M+, Joining Abbott and Edwards on the Transcatheter Mitral Valve Bandwagon
Tuesday, August 25, 2015
Source: Fierce Medical Devices
The run on independent transcatheter mitral valve replacement companies is now resembling a stampede thanks to Medtronic's ($MDT) decision to purchase Twelve, a portfolio company of medical device incubator The Foundry, for up to $458 million.
The blockbuster success of transaortic valve replacements has generated enthusiasm for the TMVR arena, which aims to extend the minimally invasive, transcatheter-based approached to the replacement of the mitral valve.